Drug delivery innovations for enhancing the anticancer potential of vitamin e isoforms and their derivatives

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Neophytou, Christiana M ^a   Constantinou, Andreas I ^a  

^a UNIVERSITY OF CYPRUS   (Cyprus)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ALPHA TOCOTRIENOL; ANTINEOPLASTIC AGENT; LIPOSOME; MACROGOL; SUCCINIC ACID; TOCOFERSOLAN; NANOPARTICLE;

ANTINEOPLASTIC ACTIVITY; BIOLOGICAL ACTIVITY; CLINICAL EVALUATION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUSTRY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG STRUCTURE; EFFECTIVE CONCENTRATION; HUMAN; INTRACELLULAR TRANSPORT; MICELLE; NANOENCAPSULATION; NONHUMAN; PHYSICAL CHEMISTRY; REVIEW; STRUCTURE ANALYSIS; ANALOGS AND DERIVATIVES; CHEMISTRY; NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

ALPHA-TOCOPHEROL; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; NANOPARTICLES; NEOPLASMS; VITAMIN E;

EID: 84934932682     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/584862     Document Type: Review

References (131)

1. M. G. Traber and J. Atkinson, "Vitamin E, antioxidant and nothing more, " Free Radical Biology and Medicine, vol. 43, no. 1, pp. 4-15, 2007.
2. Q. Jiang, "Natural forms of vitamin E: metabolism, antioxidant, and anti-inflammatory activities and their role in disease prevention and therapy, " Free Radical Biology & Medicine, vol. 72, pp. 76-90, 2014.
3. S. Khanna, S. Roy, A. Slivka et al. , "Neuroprotective properties of the natural vitamin E-tocotrienol, " Stroke, vol. 36, no. 10, pp. 2258-2264, 2005.
4. C. Constantinou, A. Papas, and A. I. Constantinou, "Vitamin E and cancer: an insight into the anticancer activities of vitamin E isomers and analogs, " International Journal of Cancer, vol. 123, no. 4, pp. 739-752, 2008.
5. B. S. Abuasal, H. Qosa, P. W. Sylvester, and A. Kaddoumi, "Comparison of the intestinal absorption and bioavailability of gamma-tocotrienol and alpha-tocopherol: in vitro, in situ and in vivo studies, " Biopharmaceutics and Drug Disposition, vol. 33, no. 5, pp. 246-256, 2012.
6. S. P. Yap, K. H. Yuen, and A. B. Lim, "Influence of route of administration on the absorption and disposition of-,-and-tocotrienols in rats, " Journal of Pharmacy and Pharmacology, vol. 55, no. 1, pp. 53-58, 2003.
7. B. Abuasal, P. W. Sylvester, and A. Kaddoumi, "Intestinal absorption of-Tocotrienol is mediated by Niemann-Pick C1-like 1: in situ rat intestinal perfusion studies, " Drug Metabolism and Disposition, vol. 38, no. 6, pp. 939-945, 2010.
8. S. Alqahtani, A. Alayoubi, S. Nazzal, P. W. Sylvester, and A. Kaddoumi, "Nonlinear absorption kinetics of self-emulsifying drug delivery systems (SEDDS) containing tocotrienols as lipophilicmolecules: in vivo and in vitro studies, " AAPS Journal, vol. 15, no. 3, pp. 684-695, 2013.
9. A. Kamal-Eldin and L.-A. Appelqvist, "The chemistry and antioxidant properties of tocopherols and tocotrienols, " Lipids, vol. 31, no. 7, pp. 671-701, 1996.
10. X.-F. Wang, L. Dong, Y. Zhao, M. Tomasetti, K. Wu, and J. Neuzil, "Vitamin E analogues as anticancer agents: lessons from studies with-tocopheryl succinate, " Molecular Nutrition & Food Research, vol. 50, no. 8, pp. 675-685, 2006.
11. J. Neuzil, "Vitamin E succinate and cancer treatment: a vitamin E prototype for selective antitumour activity, " British Journal of Cancer, vol. 89, no. 10, pp. 1822-1826, 2003.
12. M. G. Traber, T. Olivecrona, and H. J. Kayden, "Bovine milk lipoprotein lipase transfers tocopherol to human fibroblasts during triglyceride hydrolysis in vitro, " Journal of Clinical Investigation, vol. 75, no. 5, pp. 1729-1734, 1985.
13. M. G. Traber, G. W. Burton, L. Hughes et al. , "Discrimination between forms of vitamin E by humans with and without genetic abnormalities of lipoprotein metabolism, " The Journal of Lipid Research, vol. 33, no. 8, pp. 1171-1182, 1992.
14. J. K. Lodge, J. Ridlington, S. Leonard, H. Vaule, and M. G. Traber, "Alpha-and gamma-tocotrienols are metabolized to carboxyethyl-hydroxychroman derivatives and excreted in human urine, " Lipids, vol. 36, no. 1, pp. 43-48, 2001.
15. S. Fairus, R. M. Nor, H. M. Cheng, and K. Sundram, "Postprandial metabolic fate of tocotrienol-rich vitamin E differs significantly from that of-tocopherol, " American Journal of Clinical Nutrition, vol. 84, no. 4, pp. 835-842, 2006.
16. S. P. Yap, K. H. Yuen, and J. W. Wong, "Pharmacokinetics and bioavailability of-,-and-tocotrienols under different food status, " Journal of Pharmacy and Pharmacology, vol. 53, no. 1, pp. 67-71, 2001.
17. I. Ikeda, Y. Imasato, E. Sasaki, and M. Sugano, "Lymphatic transport of-,-, and-tocotrienols and-tocopherol in rats, " International Journal for Vitamin and Nutrition Research, vol. 66, no. 3, pp. 217-221, 1996.
18. S. Khanna, V. Patel, C. Rink, S. Roy, and C. K. Sen, "Delivery of orally supplemented-tocotrienol to vital organs of rats and tocopherol-transport protein deficient mice, " Free Radical Biology and Medicine, vol. 39, no. 10, pp. 1310-1319, 2005.
19. V. A. Tiurin, V. E. Kagan, N. F. Avrova, and M. P. Prozorovskaia, "Lipid asymmetry and alpha-tocopherol distribution in outer and inner monolayers of bilayer lipid membranes, " Bulletin of Experimental Biology and Medicine, vol. 105, pp. 667-669, 1988.
20. V. A. Tyurin, V. E. Kagan, E. A. Serbinova, N. V. Gorbunov, and A. N. Erin, "The interaction of alpha-tocopherol with phospholipid liposomes: the absence of transbilayer mobility, " Biulleten' Eksperimental'no Biologii i Meditsiny, vol. 102, no. 12, pp. 689-692, 1986.
21. P. Mardones and A. Rigotti, "Cellular mechanisms of vitamin e uptake: relevance in alpha-tocopherol metabolism and potential implications for disease, " Journal of Nutritional Biochemistry, vol. 15, no. 5, pp. 252-260, 2004.
22. M. G. Traber and H. J. Kayden, "Vitamin E is delivered to cells via the high affinity receptor for low-density lipoprotein, " The American Journal of Clinical Nutrition, vol. 40, no. 4, pp. 747-751, 1984.
23. C. A. Thellman and R. B. Shireman, "In vitro uptake of[3H]-tocopherol from low density lipoprotein by cultured human fibroblasts, " Journal of Nutrition, vol. 115, no. 12, pp. 1673-1679, 1985.
24. I. Kolleck, H. Wissel, F. Guthmann, M. Schlame, P. Sinha, and B. Rstow, "HDL-holoparticle uptake by alveolar type II cells: effect of vitamin E status, " The American Journal of Respiratory Cell and Molecular Biology, vol. 27, no. 1, pp. 57-63, 2002.
25. D. Goti, A. Hrzenjak, S. Levak-Frank et al. , "Scavenger receptor class B, type I is expressed in porcine brain capillary endothelial cells and contributes to selective uptake of HDL-associated vitamin E, " Journal of Neurochemistry, vol. 76, no. 2, pp. 498-508, 2001.
26. I. Kolleck, M. Schlame, H. Fechner, A. C. Looman, H. Wissel, and B. Rstow, "HDL is the major source of vitamin E for type II pneumocytes, " Free Radical Biology and Medicine, vol. 27, no. 7-8, pp. 882-890, 1999.
27. P. Mardones, P. Strobel, S. Miranda et al. , "Alpha-tocopherol metabolism is abnormal in scavenger receptor class B type I (SRBI)-deficient mice, " Journal of Nutrition, vol. 132, no. 3, pp. 443-449, 2002.
28. W. Witt, I. Kolleck, H. Fechner, P. Sinha, and B. Rstow, "Regulation by vitamin E of the scavenger receptor BI in rat liver and HepG2 cells, " Journal of Lipid Research, vol. 41, no. 12, pp. 2009-2016, 2000.
29. J. Qian, S. Morley, K. Wilson, P. Nava, J. Atkinson, andD. Manor, "Intracellular trafficking of vitamin E in hepatocytes: the role of tocopherol transfer protein, "The Journal of Lipid Research, vol. 46, no. 10, pp. 2072-2082, 2005.
30. M. Horiguchi, M. Arita, D. E. Kaempf-Rotzoll, M. Tsujimoto, K. Inoue, and H. Arai, "pH-dependent translocation of-tocopherol transfer protein (-TTP) between hepatic cytosol and late endosomes, " Genes to Cells, vol. 8, no. 10, pp. 789-800, 2003.
31. N. Kaplowitz, H. Yoshida, J. Kuhlenkamp, B. Slitsky, I. Ren, and A. Stolz, "Tocopherol-binding proteins of hepatic cytosol, " Annals of the New York Academy of Sciences, vol. 570, pp. 85-94, 1989.
32. J. B. Massey, "Kinetics of transfer of-tocopherol between model and native plasma lipoproteins, " Biochimica et Biophysica Acta, vol. 793, no. 3, pp. 387-392, 1984.
33. J. Qian, K. Wilson, P. Nava, S. Morley, J. Atkinson, andD. Manor, "Intracellular localization of-tocopherol transfer protein and-tocopherol, " Annals of the New York Academy of Sciences, vol. 1031, pp. 330-331, 2004.
34. L. Ulatowski, R. Parker, C. Davidson et al. , "Altered vitamin E status in Niemann-Pick type C disease, " Journal of Lipid Research, vol. 52, no. 7, pp. 1400-1410, 2011.
35. L. F. Yvenes, A. Klein, J. F. Castro et al. , "Lysosomal vitamin E accumulation in Niemann-Pick type C disease, " Biochimica et Biophysica Acta, vol. 1822, no. 2, pp. 150-160, 2012.
36. C. A. Drevon, "Absorption, transport and metabolism of vitamin E, " Free Radical Research Communications, vol. 14, no. 4, pp. 229-246, 1991.
37. J.-M. Zingg and A. Azzi, "Non-antioxidant activities of vitamin E, " Current Medicinal Chemistry, vol. 11, no. 9, pp. 1113-1133, 2004.
38. K. Hensley, E. J. Benaksas, R. Bolli et al. , "New perspectives on vitamin E:-tocopherol and carboxyethylhydroxychroman metabolites in biology and medicine, " Free Radical Biology and Medicine, vol. 36, no. 1, pp. 1-15, 2004.
39. F. Berrino and P. Muti, "Mediterranean diet and cancer, " European Journal of Clinical Nutrition, vol. 43, supplement 2, pp. 49-55, 1989.
40. M. Khlat, "Cancer inMediterranean migrants-based on studies in France and Australia, " Cancer Causes and Control, vol. 6, no. 6, pp. 525-531, 1995.
41. O. P. Heinonen, D. Albanes, J. Virtamo et al. , "Prostate cancer and supplementation with-tocopherol and-carotene: incidence and mortality in a controlled trial, " Journal of theNational Cancer Institute, vol. 90, no. 6, pp. 440-446, 1998.
42. M. E. Wright, S. J. Weinstein, K. A. Lawson et al. , "Supplemental and dietary vitamin E intakes and risk of prostate cancer in a large prospective study, " Cancer Epidemiology Biomarkers and Prevention, vol. 16, no. 6, pp. 1128-1135, 2007.
43. H. L. Parnes, M. G. House, J. Kagan et al. , "Prostate cancer chemoprevention agent development: the National Cancer Institute, Division of Cancer Prevention portfolio, " Journal of Urology, vol. 171, no. 2, pp. S68-S75, 2004.
44. T. Weber, M. Lu, L. Andera et al. , "Vitamin E succinate is a potent novel antineoplastic agent with high selectivity and cooperativity with tumor necrosis factor-related apoptosisinducing ligand (Apo2 ligand) in vivo, " Clinical Cancer Research, vol. 8, no. 3, pp. 863-869, 2002.
45. H. Ahsan, A. Ahad, J. Iqbal, andW. A. Siddiqui, "Pharmacological potential of tocotrienols: a review, " Nutrition & Metabolism, vol. 11, no. 1, article 52, 2014.
46. S. J. Shah and P. W. Sylvester, "-tocotrienol inhibits neoplastic mammary epithelial cell proliferation by decreasing Akt and nuclear factor B activity, " Experimental Biology and Medicine, vol. 230, no. 4, pp. 235-241, 2005.
47. K. S. Ahn, G. Sethi, K. Krishnan, and B. B. Aggarwal, "Gammatocotrienol inhibits nuclear factor-kappaB signaling pathway through inhibition of receptor-interacting protein and TAK1 leading to suppression of antiapoptotic gene products and potentiation of apoptosis, " The Journal of Biological Chemistry, vol. 282, no. 1, pp. 809-820, 2007.
48. M. Sakai, M. Okabe, H. Tachibana, and K. Yamada, "Apoptosis induction by-tocotrienol in human hepatoma Hep3B cells, " Journal of Nutritional Biochemistry, vol. 17, no. 10, pp. 672-676, 2006.
49. Y. Li, T. Hahn, K. Garrison et al. , "The vitamin E analogue-TEA stimulates tumor autophagy and enhances antigen crosspresentation, " Cancer Research, vol. 72, no. 14, pp. 3535-3545, 2012.
50. R. Tiwary, W. Yu, B. G. Sanders, and K. Kline, "-TEA cooperates with chemotherapeutic agents to induce apoptosis of p53 mutant, triple-negative human breast cancer cells via activating p73, " Breast Cancer Research, vol. 13, no. 1, article R1, 2011.
51. R. Tiwary, W. Yu, B. G. Sanders, and K. Kline, "-TEA cooperates with MEK or mTOR inhibitors to induce apoptosis via targeting IRS/PI3K pathways, " British Journal of Cancer, vol. 104, no. 1, pp. 101-109, 2011.
52. K. Anderson, M. Simmons-Menchaca, K. A. Lawson, J. Atkinson, B. G. Sanders, and K. Kline, "Differential response of human ovarian cancer cells to induction of apoptosis by vitamin E succinate and vitamin E analogue,-TEA, " Cancer Research, vol. 64, no. 12, pp. 4263-4269, 2004.
53. K. A. Lawson, K. Anderson, M. Menchaca et al. , "Novel vitamin E analogue decreases syngeneic mouse mammary tumor burden and reduces lung metastasis, " Molecular Cancer Therapeutics, vol. 2, no. 5, pp. 437-444, 2003.
54. J. Neuzil, L.-F. Dong, J. Rohlena, J. Truksa, and S. J. Ralph, "Classification of mitocans, anti-cancer drugs acting on mitochondria, " Mitochondrion, vol. 13, no. 3, pp. 199-208, 2013.
55. J. Neuzil, T. Weber, A. Schrder et al. , "Induction of cancer cell apoptosis by-tocopheryl succinate: molecular pathways and structural requirements, " The FASEB Journal, vol. 15, no. 2, pp. 403-415, 2001.
56. R. Tiwary, W. Yu, J. Li, S.-K. Park, B. G. Sanders, and K. Kline, "Role of endoplasmic reticulum stress in-tea mediated TRAIL/DR5 death receptor dependent apoptosis, " PLoS ONE, vol. 5, no. 7, Article IDe11865, 2010.
57. C. Wadsack, A. Hrzenjak, A. Hammer et al. , "Trophoblastlike human choriocarcinoma cells serve as a suitable in vitro model for selective cholesteryl ester uptake from high density lipoproteins, " European Journal of Biochemistry, vol. 270, no. 3, pp. 451-462, 2003.
58. C. Wadsack, B. Hirschmugl, A. Hammer et al. , "Scavenger receptor class B, type I on non-malignant andmalignant human epithelial cells mediates cholesteryl ester-uptake from high density lipoproteins, "The International Journal of Biochemistry &Cell Biology, vol. 35, no. 4, pp. 441-454, 2003.
59. A. Hrzenjak, H. Reicher, A. Wintersperger et al. , "Inhibition of lung carcinoma cell growth by high density lipoproteinassociated-tocopheryl-succinate, " Cellular and Molecular Life Sciences, vol. 61, no. 12, pp. 1520-1531, 2004.
60. J. Neuzil, L.-F. Dong, L. Ramanathapuram et al. , "Vitamin E analogues as a novel group of mitocans: anti-cancer agents that act by targeting mitochondria, " Molecular Aspects of Medicine, vol. 28, no. 5-6, pp. 607-645, 2007.
61. L. F. Dong, V. J. Jameson, D. Tilly et al. , "Mitochondrial targeting of alpha-tocopheryl succinate enhances its pro-apoptotic efficacy: a new paradigm for effective cancer therapy, " Free Radical Biology & Medicine, vol. 50, pp. 1546-1555, 2011.
62. R. A. J. Smith, C. M. Porteous, A. M. Gane, and M. P. Murphy, "Delivery of bioactive molecules to mitochondria in vivo, " Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 9, pp. 5407-5412, 2003.
63. J. Kovarova, M. Bajzikova, M. Vondrusova et al. , "Mitochondrial targeting of-tocopheryl succinate enhances its antimesothelioma efficacy, " Redox Report, vol. 19, no. 1, pp. 16-25, 2014.
64. J. Truksa, L. F. Dong, J. Rohlena et al. , "Mitochondrially targeted vitamin e succinate modulates expression of mitochondrial DNAtranscripts andmitochondrial biogenesis, " Antioxidants& Redox Signaling, vol. 22, no. 11, pp. 883-900, 2015.
65. S. Hama, S. Utsumi, Y. Fukuda et al. , "Development of a novel drug delivery system consisting of an antitumor agent tocopheryl succinate, " Journal of Controlled Release, vol. 161, no. 3, pp. 843-851, 2012.
66. Y. Matsumura and H. Maeda, "A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs, " Cancer Research, vol. 46, no. 12 I, pp. 6387-6392, 1986.
67. K. Greish, "Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting, " Methods inMolecular Biology, vol. 624, pp. 25-37, 2010.
68. A. Tomic-Vatic, J. Eytina, J. Chapman, E. Mahdavian, J. Neuzil, and B. A. Salvatore, "Vitamin E amides, a new class of vitamin E analogues with enhanced proapoptotic activity, " International Journal of Cancer, vol. 117, no. 2, pp. 188-193, 2005.
69. J. Turnek, X.-F. Wang, P. Kntigov et al. , "Liposomal formulation of-tocopheryl maleamide: in vitro and in vivo toxicological profile and anticancer effect against spontaneous breast carcinomas in mice, " Toxicology and Applied Pharmacology, vol. 237, no. 3, pp. 249-257, 2009.
70. K. A. Lawson, K. Anderson, R. M. Snyder et al. , "Novel vitamin E analogue and 9-nitro-camptothecin administered as liposome aerosols decrease syngeneic mouse mammary tumor burden and inhibit metastasis, " Cancer Chemotherapy and Pharmacology, vol. 54, no. 5, pp. 421-431, 2004.
71. H. Montazeri Aliabadi, D. R. Brocks, and A. Lavasanifar, "Polymeric micelles for the solubilization and delivery of cyclosporine A: pharmacokinetics and biodistribution, " Biomaterials, vol. 26, no. 35, pp. 7251-7259, 2005.
72. V. P. Torchilin, "Micellar nanocarriers: pharmaceutical perspectives, " Pharmaceutical Research, vol. 24, no. 1, pp. 1-16, 2007.
73. H. Maeda, J. Wu, T. Sawa, Y. Matsumura, and K. Hori, "Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review, " Journal of Controlled Release, vol. 65, no. 1-2, pp. 271-284, 2000.
74. N. Liang, S. Sun, X. Li, H. Piao, F. Cui, and L. Fang, "Alphatocopherol succinate-modified chitosan as a micellar delivery system for paclitaxel: preparation, characterization and in vitro/in vivo evaluations, " International Journal of Pharmaceutics, vol. 423, no. 2, pp. 480-488, 2012.
75. J. Emami, M. Rezazadeh, M. Rostami et al. , "Co-delivery of paclitaxel and-tocopherol succinate by novel chitosan-based polymeric micelles for improving micellar stability and efficacious combination therapy, " Drug Development and Industrial Pharmacy, pp. 1-11, 2014.
76. H. Akita, R. Ishiba, H. Hatakeyama et al. , "A neutral envelopetype nanoparticle containing pH-responsive and SS-cleavable lipid-like material as a carrier for plasmid DNA, " Advanced Healthcare Materials, vol. 2, no. 8, pp. 1120-1125, 2013.
77. H. Akita, R. Ishiba, R. Togashi et al. , "A neutral lipid envelopetype nanoparticle composed of a pH-activated and vitamin E-scaffold lipid-like material as a platform for a gene carrier targeting renal cell carcinoma, " Journal of Controlled Release, vol. 200, pp. 97-105, 2015.
78. J. Y. Fu, D. R. Blatchford, L. Tetley, andC. Dufès, "Tumor regression after systemic administration of tocotrienol entrapped in tumor-targeted vesicles, " Journal of Controlled Release, vol. 140, no. 2, pp. 95-99, 2009.
79. J. Y. Fu, W. Zhang, D. R. Blatchford, L. Tetley, G. McConnell, and C. Dufès, "Novel tocotrienol-entrapping vesicles can eradicate solid tumors after intravenous administration, " Journal of Controlled Release, vol. 154, no. 1, pp. 20-26, 2011.
80. A. B. Shirode and P. W. Sylvester, "Synergistic anticancer effects of combined-tocotrienol and celecoxib treatment are associatedwith suppression in Akt andNFB signaling, " Biomedicine and Pharmacotherapy, vol. 64, no. 5, pp. 327-332, 2010.
81. S. V. Bachawal, V. B. Wali, and P. W. Sylvester, "Combined-tocotrienol and erlotinib/gefitinib treatment suppresses Stat and Akt signaling inmurinemammary tumor cells, " Anticancer Research, vol. 30, no. 2, pp. 429-437, 2010.
82. V. B. Wali and P. W. Sylvester, "Synergistic antiproliferative effects of-tocotrienol and statin treatment on mammary tumor cells, " Lipids, vol. 42, no. 12, pp. 1113-1123, 2007.
83. M. M. Fryd and T. G. Mason, "Advanced nanoemulsions, " Annual Review of Physical Chemistry, vol. 63, pp. 493-518, 2012.
84. A. Y. Alayoubi, J. F. Anderson, S. D. Satyanarayanajois, P. W. Sylvester, and S. Nazzal, "Concurrent delivery of tocotrienols and simvastatin by lipid nanoemulsions potentiates their antitumor activity against human mammary adenocarcenoma cells, " European Journal of Pharmaceutical Sciences, vol. 48, no. 3, pp. 385-392, 2013.
85. J. Pham, A. Nayel, C. Hoang, and T. Elbayoumi, "Enhanced effectiveness of tocotrienol-based nano-emulsified system for topical delivery against skin carcinomas, " Drug Delivery, pp. 1-11, 2014.
86. M. Nasr, N. Nafee, H. Saad, and A. Kazem, "Improved antitumor activity and reduced cardiotoxicity of epirubicin using hepatocyte-targeted nanoparticles combined with tocotrienols against hepatocellular carcinoma in mice, " European Journal of Pharmaceutics and Biopharmaceutics, vol. 88, no. 1, pp. 216-225, 2014.
87. Z. Zhang, S. Tan, and S. S. Feng, "Vitamin E TPGS as a molecular biomaterial for drug delivery, " Biomaterials, vol. 33, pp. 4889-4906, 2012.
88. Y. Guo, J. Luo, S. Tan, B. O. Otieno, and Z. Zhang, "The applications of Vitamin e TPGS in drug delivery, " European Journal of Pharmaceutical Sciences, vol. 49, no. 2, pp. 175-186, 2013.
89. M. G. Traber, T. D. Schiano, A. C. Steephen, H. J. Kayden, and M. Shike, "Efficacy of water-soluble vitamin E in the treatment of vitamin E malabsorption in short-bowel syndrome, " The American Journal of Clinical Nutrition, vol. 59, no. 6, pp. 1270-1274, 1994.
90. R. J. Sokol, N. Butler-Simon, C. Conner et al. , "Multicenter trial of d-tocopheryl polyethylene glycol 1000 succinate for treatment of vitamin E deficiency in children with chronic cholestasis, " Gastroenterology, vol. 104, no. 6, pp. 1727-1735, 1993.
91. R. J. Sokol, N. A. Butler-Simon, D. Bettis, D. J. Smith, and A. Silverman, "Tocopheryl polyethylene glycol 1000 succinate therapy for vitamin E deficiency during chronic childhood cholestasis: neurologic outcome, " The Journal of Pediatrics, vol. 111, no. 6, pp. 830-836, 1987.
92. P. P. Constantinides, J. Han, and S. S. Davis, "Advances in the use of tocols as drug delivery vehicles, " Pharmaceutical Research, vol. 23, no. 2, pp. 243-255, 2006.
93. M. V. S. Varma and R. Panchagnula, "Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo, " European Journal of Pharmaceutical Sciences, vol. 25, no. 4-5, pp. 445-453, 2005.
94. W. J. Krasavage and C. J. Terhaar, "d-tocopheryl poly(ethylene glycol) 1000 succinate: acute toxicity, subchronic feeding, reproduction, and teratologic studies in the rat, " Journal of Agricultural and Food Chemistry, vol. 25, no. 2, pp. 273-278, 1977.
95. EFSA Panel on Food Additives-Flavourings-Processing Aids and Materials in Contact with Food (AFC), "Opinion of the Scientific Panel on food additives, flavourings, processing aids and materials in contact with food (AFC) related to D-alphatocopheryl polyethylene glycol 1000 succinate (TPGS) in use for food for particular nutritional purposes, " EFSA Journal, 2007, http://www. efsa. europa. eu/en/efsajournal/pub/490. htm.
96. M. G. Traber, C. A. Thellman, M. J. Rindler, and H. J. Kayden, "Uptake of intact TPGS (d-tocopheryl polyethylene glycol 1000 succinate) a water-miscible form of vitamin E by human cells in vitro, " The American Journal of Clinical Nutrition, vol. 48, no. 3, pp. 605-611, 1988.
97. L. Mu and S. S. Feng, "Vitamin E TPGS used as emulsifier in the solvent evaporation/extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel (Taxol), " Journal of Controlled Release, vol. 80, no. 1-3, pp. 129-144, 2002.
98. J. Pan, Y. Wang, and S.-S. Feng, "Formulation, characterization, and in vitro evaluation of quantum dots loaded in poly(Lactide)-Vitamin E TPGS nanoparticles for cellular and molecular imaging, " Biotechnology and Bioengineering, vol. 101, no. 3, pp. 622-633, 2008.
99. J. M. Dintaman and J. A. Silverman, "Inhibition of Pglycoprotein byD-tocopheryl polyethylene glycol 1000 succinate (TPGS), " Pharmaceutical Research, vol. 16, no. 10, pp. 1550-1556, 1999.
100. L. Mu, T. A. Elbayoumi, and V. P. Torchilin, "Mixed micelles made of poly(ethylene glycol)-phosphatidylethanolamine conjugate and D-tocopheryl polyethylene glycol 1000 succinate as pharmaceutical nanocarriers for camptothecin, " International Journal of Pharmaceutics, vol. 306, no. 1-2, pp. 142-149, 2005.
101. S.-S. Feng, "New-concept chemotherapy by nanoparticles of biodegradable polymers: where are we now" Nanomedicine, vol. 1, no. 3, pp. 297-309, 2006.
102. K. Y. Win and S.-S. Feng, "In vitro and in vivo studies on vitamin E TPGS-emulsified poly(D, L-lactic-co-glycolic acid) nanoparticles for paclitaxel formulation, " Biomaterials, vol. 27, no. 10, pp. 2285-2291, 2006.
103. P. Parhi, C. Mohanty, and S. K. Sahoo, "Enhanced cellular uptake and in vivo pharmacokinetics of rapamycin-loaded cubic phase nanoparticles for cancer therapy, " Acta Biomaterialia, vol. 7, no. 10, pp. 3656-3669, 2011.
104. C. S. Muenyi, Cell Toxicology Study of RRR-Alpha-Tocopheryl Polyethylene Glycol 1000 Succinate (TPGS), East Tennessee State University, 2005.
105. H.-J. Youk, E. Lee, M.-K. Choi et al. , "Enhanced anticancer efficacy of-tocopheryl succinate by conjugation with polyethylene glycol, " Journal of Controlled Release, vol. 107, no. 1, pp. 43-52, 2005.
106. C. Constantinou, C. M. Neophytou, P. Vraka, J. A. Hyatt, K. A. Papas, and A. I. Constantinou, "Induction of DNA damage and caspase-independent programmed cell death by vitamin E, " Nutrition and Cancer, vol. 64, no. 1, pp. 136-152, 2012.
107. C. M. Neophytou, C. Constantinou, P. Papageorgis, and A. I. Constantinou, "D-alpha-tocopheryl polyethylene glycol succinate (TPGS) induces cell cycle arrest and apoptosis selectively in Survivin-overexpressing breast cancer cells, " Biochemical Pharmacology, vol. 89, no. 1, pp. 31-42, 2014.
108. M. di Cagno, P. C. Stein, J. Styskala, J. Hlavc, N. Skalko-Basnet, and A. Bauer-Brandl, "Overcoming instability and low solubility of new cytostatic compounds: a comparison of two approaches, " European Journal of Pharmaceutics and Biopharmaceutics, vol. 80, no. 3, pp. 657-662, 2012.
109. L. Yu, A. Bridgers, J. Polli et al. , "Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability, " Pharmaceutical Research, vol. 16, no. 12, pp. 1812-1817, 1999.
110. T. Chang, L. Z. Benet, and M. F. Hebert, "The effect of watersoluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers, " Clinical Pharmacology andTherapeutics, vol. 59, no. 3, pp. 297-303, 1996.
111. J. Brouwers, J. Tack, F. Lammert, and P. Augustijns, "Intraluminal drug and formulation behavior and integration in in vitro permeability estimation: a case study with amprenavir, " Journal of Pharmaceutical Sciences, vol. 95, no. 2, pp. 372-383, 2006.
112. E.-M. Collnot, C. Baldes, M. F. Wempe et al. , "Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: influence on ATPase activity and membrane fluidity, " Molecular Pharmaceutics, vol. 4, no. 3, pp. 465-474, 2007.
113. U. Hanke, K. May, V. Rozehnal, S. Nagel, W. Siegmund, and W. Weitschies, "Commonly used nonionic surfactants interact differently with the human efflux transporters ABCB1 (p-glycoprotein) and ABCC2 (MRP2), " European Journal of Pharmaceutics and Biopharmaceutics, vol. 76, no. 2, pp. 260-268, 2010.
114. E.-M. Collnot, C. Baldes, M. F. Wempe et al. , "Influence of vitamin E TPGS poly(ethylene glycol) chain length on apical efflux transporters in Caco-2 cell monolayers, " Journal of Controlled Release, vol. 111, no. 1-2, pp. 35-40, 2006.
115. A. Christiansen, T. Backensfeld, K. Denner, andW. Weitschies, "Effects of non-ionic surfactants on cytochrome P450-mediated metabolism in vitro, " European Journal of Pharmaceutics and Biopharmaceutics, vol. 78, no. 1, pp. 166-172, 2011.
116. M.-J. Shieh, C.-Y. Hsu, L.-Y. Huang, H.-Y. Chen, F.-H. Huang, and P.-S. Lai, "Reversal of doxorubicin-resistance bymultifunctional nanoparticles inMCF-7/ADR cells, " Journal of Controlled Release, vol. 152, no. 3, pp. 418-425, 2011.
117. P. Yu, H. Yu, C. Guo et al. , "Reversal of doxorubicin resistance in breast cancer by mitochondria-targeted pH-responsive micelles, " Acta Biomaterialia, vol. 14, pp. 115-124, 2015.
118. S. Wang, R. Chen, J. Morott, M. A. Repka, Y. Wang, and M. Chen, "mPEG-b-PCL/TPGS mixed micelles for delivery of resveratrol in overcoming resistant breast cancer, " Expert Opinion on Drug Delivery, vol. 12, no. 3, pp. 361-373, 2015.
119. J. Zhao and S.-S. Feng, "Effects of PEG tethering chain length of vitamin E TPGS with a Herceptin-functionalized nanoparticle formulation for targeted delivery of anticancer drugs, " Biomaterials, vol. 35, no. 10, pp. 3340-3347, 2014.
120. M. S. Muthu, S. A. Kulkarni, J. Xiong, andS.-S. Feng, "Vitamine TPGS coated liposomes enhanced cellular uptake and cytotoxicity of docetaxel in brain cancer cells, " International Journal of Pharmaceutics, vol. 421, no. 2, pp. 332-340, 2011.
121. M. S. Muthu, R. V. Kutty, Z. Luo, J. Xie, and S. S. Feng, "Theranostic vitamin E TPGS micelles of transferrin conjugation for targeted co-delivery of docetaxel and ultra bright gold nanoclusters, " Biomaterials, vol. 39, pp. 234-248, 2015.
122. Y. Mi, J. Zhao, and S.-S. Feng, "Vitamin e TPGS prodrug micelles for hydrophilic drug delivery with neuroprotective effects, " International Journal of Pharmaceutics, vol. 438, no. 1-2, pp. 98-106, 2012.
123. W. Lv, L. Cheng, and B. Li, "Development and evaluation of a novel TPGS-mediated paclitaxel-loaded PLGA-mPEG nanoparticle for the treatment of ovarian cancer, " Chemical and Pharmaceutical Bulletin, vol. 63, no. 2, pp. 68-74, 2015.
124. Y. Sun, B. Yu, G. Wang et al. , "Enhanced antitumor efficacy of vitamin E TPGS-emulsified PLGA nanoparticles for delivery of paclitaxel, " Colloids and Surfaces B: Biointerfaces, vol. 123, pp. 716-723, 2014.
125. D. Pooja, H. Kulhari, M. K. Singh, S. Mukherjee, S. S. Rachamalla, and R. Sistla, "Dendrimer-TPGS mixed micelles for enhanced solubility and cellular toxicity of taxanes, " Colloids and Surfaces B: Biointerfaces, vol. 121, pp. 461-468, 2014.
126. D. de Melo-Diogo, V. M. Gaspar, E. C. Costa et al. , "Combinatorial delivery of Crizotinib-Palbociclib-Sildenafil using TPGSPLA micelles for improved cancer treatment, " European Journal of Pharmaceutics and Biopharmaceutics, vol. 88, no. 3, pp. 718-729, 2014.
127. Y. Mi, Y. Liu, and S.-S. Feng, "Formulation of Docetaxel by folic acid-conjugated D-tocopheryl polyethylene glycol succinate 2000 (Vitamin E TPGS2) micelles for targeted and synergistic chemotherapy, " Biomaterials, vol. 32, no. 16, pp. 4058-4066, 2011.
128. N. Duhem, F. Danhier, V. Pourcelle et al. , "Self-assembling doxorubicin-tocopherol succinate prodrug as a new drug delivery system: synthesis, characterization, and in vitro and in vivo anticancer activity, " Bioconjugate Chemistry, vol. 25, no. 1, pp. 72-81, 2014.
129. S. Abbad, C. Wang, A. Y. Waddad, H. Lv, and J. Zhou, "Preparation, in vitro and in vivo evaluation of polymeric nanoparticles based on hyaluronic acid-poly(butyl cyanoacrylate) and Dalpha-tocopheryl polyethylene glycol 1000 succinate for tumortargeted delivery of morin hydrate, " International Journal of Nanomedicine, vol. 10, pp. 305-320, 2015.
130. Y. H. Ibrahim, C. Garc-Garc, V. Serra et al. , "PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition, " Cancer Discovery, vol. 2, no. 11, pp. 1036-1047, 2012.
131. G. Orive, E. Anitua, J. L. Pedraz, and D. F. Emerich, "Biomaterials for promoting brain protection, repair and regeneration, " Nature Reviews Neuroscience, vol. 10, no. 9, pp. 682-692, 2009.